Invention Grant
US09334496B2 Antisense EGFRAS guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
有权
反义EGFRAS胍基核酸(GPNA)寡核苷酸作为抗肿瘤剂
- Patent Title: Antisense EGFRAS guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
- Patent Title (中): 反义EGFRAS胍基核酸(GPNA)寡核苷酸作为抗肿瘤剂
-
Application No.: US13107344Application Date: 2011-05-13
-
Publication No.: US09334496B2Publication Date: 2016-05-10
- Inventor: Jennifer Rubin Grandis , Sufi Mary Thomas , Danith H. Ly
- Applicant: Jennifer Rubin Grandis , Sufi Mary Thomas , Danith H. Ly
- Applicant Address: US PA Pittsburgh US PA Pittsburgh US PA Pittsburgh
- Assignee: EYE & EAR FOUNDATION,UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION,CARNEGIE MELLON UNIVERSITY
- Current Assignee: EYE & EAR FOUNDATION,UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION,CARNEGIE MELLON UNIVERSITY
- Current Assignee Address: US PA Pittsburgh US PA Pittsburgh US PA Pittsburgh
- Agency: Baker Botts L.L.P.
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C12N15/113

Abstract:
A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.
Public/Granted literature
- US20110306562A1 Antisense EGFRAS Guanidinium Peptide Nucleic Acid (GPNA) Oligonucleotides as Antitumor Agents Public/Granted day:2011-12-15
Information query
IPC分类: